N. Manamley

Most-cited papers

1. Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study

   Peter Choi, M. Farouk, N. Manamley, J. Addison

   2013Advances in Therapy28 citations Open access

   Semantic Scholar

   Save

2. Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study

   F. Schaefer, B. Hoppe, T. Jungraithmayr, G. Klaus +5 more

   2015Pediatric nephrology (Berlin, West)21 citations Open access

   Semantic Scholar

   Save

3. Data sharing and the evolving role of statisticians

   N. Manamley, S. Mallett, M. Sydes, Sally Hollis +3 more

   2016BMC Medical Research Methodology19 citations Open access

   Semantic Scholar

   Save

4. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis

   S. Roger, E. Kolmakova, Maple M. Fung, R. Malecki +5 more

   2014Nephrology7 citations

   Semantic Scholar

   Save

5. Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study

   J. Donck, Lourdes González-Tabarés, J. Chanliau, Heike Martin +4 more

   2014Advances in Therapy6 citations Open access

   Semantic Scholar

   Save

6. Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study

   J. Galle, J. Addison, M. Suranyi, K. Claes +8 more

   2016Nephrology, Dialysis and Transplantation3 citations Open access

   Semantic Scholar

   Save

7. THU-291 Non-ceruloplasmin bound copper measured by speciation assay: prospective evaluation over 12 months in real world setting of unstable Wilson disease patients

   Michael L. Schilsky, Amanda Cheung, Valentina Medici, R. Gonzalez-Peralta +9 more

   2026Journal of Hepatology0 citations

   Semantic Scholar

   Save

8. THU-298 Non-ceruloplasmin bound copper measured by speciation assay: response to therapy over 12 months in real world setting of newly diagnosed Wilson disease patients

   Michael L. Schilsky, Amanda Cheung, Valentina Medici, R. Gonzalez-Peralta +9 more

   2026Journal of Hepatology0 citations

   Semantic Scholar

   Save

9. THU-272 The pharmacokinetic profile of a new trientine tetrahydrochloride formulation supports simpler once-daily dosing for the treatment of wilson disease: results of the triumph-3 study

   K. Weiss, T. Ashdown, U. Lorch, Carla Bennett +3 more

   2026Journal of Hepatology0 citations

   Semantic Scholar

   Save

10. LBP-038 A novel trientine tetrahydrochloride formulation administered once-a-day for people living with Wilson disease: results from a phase 2 study

    E. Tsochatzis, Andrew Holt, Elaine Kamara, S. Shribman +9 more

    2026Journal of Hepatology0 citations

    Semantic Scholar

    Save

11. FACTORS INFLUENCING THE FIRST DARBEPOETIN ALFA DOSING FREQUENCY CHANGE IN CKD PATIENTS NOT ON DIALYSIS

    J. Galle, K. Claes, S. Di Giulio, A. Guérin +8 more

    20130 citations

    Semantic Scholar

    Save

12. Pathophysiology and clinical studies in CKD 5D

    Ryuichirou Konda, T. Osawa, Tatsuru Nozawa, J. Sugimura +173 more

    20110 citations Open access

    Semantic Scholar

    Save